Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is emerging as a notable player in the biopharmaceutical industry, transitioning from a development-stage company to a commercial entity with the FDA-approved therapy LYMPHIR™. This strategic shift, underscored by the drug's successful launch and a diversified pipeline, highlights the company's potential to address significant unmet medical needs across multiple therapeutic areas.
The approval and subsequent commercial launch of LYMPHIR™ (denileukin diftitox-cxdl) in December 2025 marked a pivotal milestone for Citius. This targeted immunotherapy, approved for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, generated $5.6 million in net revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. The strong market reception is further evidenced by payer coverage representing nearly 100% of covered commercial lives and 83% of targeted accounts achieving formulary inclusion or under active review as of May 2026. Additionally, Citius Oncology, the company's subsidiary, has begun expanding LYMPHIR's reach internationally, with an initial shipment to Europe in April 2026.
Beyond its approved indication, Citius is exploring LYMPHIR's potential in other oncology settings. Investigator-initiated studies have evaluated the drug in combination with pembrolizumab for recurrent or refractory gynecologic cancers and prior to commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. Positive topline results from both Phase 1 studies were reported in fiscal 2026, suggesting broader application possibilities.
The company's late-stage pipeline includes Mino-Lok®, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections pose serious risks, particularly for cancer and hemodialysis patients. Mino-Lok® aims to eradicate infection while preserving the catheter, avoiding complications associated with catheter removal and reinsertion. The therapy met primary and secondary endpoints in a pivotal Phase 3 trial and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. Following a Type C meeting, the company received guidance outlining a pathway to support a future New Drug Application submission. Citius estimates worldwide sales potential of approximately $1.8 billion for Mino-Lok®.
Another promising candidate is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With an estimated 10 million people in the U.S. reporting hemorrhoid symptoms annually, and no FDA-approved prescription products currently available, Halo-Lido could become the first such treatment if approved. The company completed a Phase 2b study in 2023 and has engaged with the FDA on next steps.
Citius is also advancing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) as a potential therapy for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. Interim results from a proof-of-concept sheep model showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls, warranting further studies.
The company's leadership team brings extensive experience in pharmaceutical development and commercialization. CEO Leonard Mazur has approximately five decades of industry experience, including founding multiple pharmaceutical companies. Executive Vice Chairman Myron Holubiak previously served as president of Roche Laboratories and held various sales and marketing roles during a 19-year career with Roche. This expertise supports Citius's strategy of advancing differentiated therapies from development to commercialization.
With LYMPHIR generating commercial revenue and a pipeline of late-stage assets, Citius Pharmaceuticals is positioned for potential growth. The combination of an approved product and multiple development programs offers several paths for value creation, addressing critical-care indications with significant unmet needs. As the company continues to engage with regulatory authorities and expand its commercial footprint, it remains a focal point for investors monitoring the biopharmaceutical sector.
